These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34537841)

  • 1. Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection.
    Alonso CD; Kelly CP; Garey KW; Gonzales-Luna AJ; Williams D; Daugherty K; Cuddemi C; Villafuerte-Gálvez J; White NC; Chen X; Xu H; Sprague R; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
    Clin Infect Dis; 2022 Jul; 74(12):2142-2149. PubMed ID: 34537841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline stool toxin concentration is associated with risk of recurrence in children with
    Sandora TJ; Kociolek LK; Williams DN; Daugherty K; Geer C; Cuddemi C; Chen X; Xu H; Savage TJ; Banz A; Garey KW; Gonzales-Luna AJ; Kelly CP; Pollock NR
    Infect Control Hosp Epidemiol; 2023 Sep; 44(9):1403-1409. PubMed ID: 36624698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.
    Pollock NR; Banz A; Chen X; Williams D; Xu H; Cuddemi CA; Cui AX; Perrotta M; Alhassan E; Riou B; Lantz A; Miller MA; Kelly CP
    Clin Infect Dis; 2019 Jan; 68(1):78-86. PubMed ID: 29788296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.
    Kelly CP; Chen X; Williams D; Xu H; Cuddemi CA; Daugherty K; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
    Clin Infect Dis; 2020 Mar; 70(6):1083-1093. PubMed ID: 31211839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Cycle Threshold, Toxin Concentration, and Clinical Characteristics of Clostridioides difficile Infection in Patients with Discordant Diagnostic Test Results.
    Shah MD; Balada-Llasat JM; Coe K; Reed E; Sandlund J; Pancholi P
    J Clin Microbiol; 2020 Apr; 58(5):. PubMed ID: 32051264
    [No Abstract]   [Full Text] [Related]  

  • 7. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.
    Guh AY; Hatfield KM; Winston LG; Martin B; Johnston H; Brousseau G; Farley MM; Wilson L; Perlmutter R; Phipps EC; Dumyati GK; Nelson D; Hatwar T; Kainer MA; Paulick AL; Karlsson M; Gerding DN; McDonald LC
    Clin Infect Dis; 2019 Oct; 69(10):1667-1674. PubMed ID: 30615074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the Association Between Diagnostic Testing Method, Polymerase Chain Reaction Ribotype, and Clinical Outcomes From Clostridioides difficile Infection: One Institution's Experience.
    Menon A; Perry DA; Motyka J; Weiner S; Standke A; Penkevich A; Keidan M; Young VB; Rao K
    Clin Infect Dis; 2021 Nov; 73(9):e2883-e2889. PubMed ID: 32930705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients.
    Miller R; Morillas JA; Brizendine KD; Fraser TG
    J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31896665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool.
    Song L; Zhao M; Duffy DC; Hansen J; Shields K; Wungjiranirun M; Chen X; Xu H; Leffler DA; Sambol SP; Gerding DN; Kelly CP; Pollock NR
    J Clin Microbiol; 2015 Oct; 53(10):3204-12. PubMed ID: 26202120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stool Interleukin-1β Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea.
    Villafuerte Gálvez JA; Pollock NR; Alonso CD; Chen X; Xu H; Wang L; White N; Banz A; Miller M; Daugherty K; Gonzalez-Luna AJ; Barrett C; Sprague R; Garey KW; Kelly CP
    Clin Infect Dis; 2023 Feb; 76(3):e1467-e1475. PubMed ID: 35906836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay.
    Hansen G; Young S; Wu AHB; Herding E; Nordberg V; Mills R; Griego-Fullbright C; Wagner A; Ong CM; Lewis S; Yoon J; Estis J; Sandlund J; Friedland E; Carroll KC
    J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31434724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
    Humphries RM; Uslan DZ; Rubin Z
    J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Agreement Between an Ultrasensitive Clostridioides difficile Toxin Assay and a C. difficile Laboratory Algorithm Utilizing GDH-and-Toxin Enzyme Immunoassays and Cytotoxin Testing.
    Landry ML; Topal JE; Estis J; Katzenbach P; Nolan N; Sandlund J
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31776192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital.
    Kim J; Pai H; Seo MR; Kang JO
    J Korean Med Sci; 2011 Oct; 26(10):1258-64. PubMed ID: 22022175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype.
    Lin Q; Pollock NR; Banz A; Lantz A; Xu H; Gu L; Gerding DN; Garey KW; Gonzales-Luna AJ; Zhao M; Song L; Duffy DC; Kelly CP; Chen X
    Clin Infect Dis; 2020 Jun; 70(12):2628-2633. PubMed ID: 31400280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.
    Polage CR; Gyorke CE; Kennedy MA; Leslie JL; Chin DL; Wang S; Nguyen HH; Huang B; Tang YW; Lee LW; Kim K; Taylor S; Romano PS; Panacek EA; Goodell PB; Solnick JV; Cohen SH
    JAMA Intern Med; 2015 Nov; 175(11):1792-801. PubMed ID: 26348734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
    Louie T; Golan Y; Khanna S; Bobilev D; Erpelding N; Fratazzi C; Carini M; Menon R; Ruisi M; Norman JM; Faith JJ; Olle B; Li M; Silber JL; Pardi DS
    JAMA; 2023 Apr; 329(16):1356-1366. PubMed ID: 37060545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Clinical Specificity with Ultrasensitive Detection of Clostridioides difficile Toxins: Reduction of Overdiagnosis Compared to Nucleic Acid Amplification Tests.
    Sandlund J; Estis J; Katzenbach P; Nolan N; Hinson K; Herres J; Pero T; Peterson G; Schumaker JM; Stevig C; Warren R; West T; Chow SK
    J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31434726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.